The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study.
 
Ming Lu
No Relationships to Disclose
 
Panpan Zhang
No Relationships to Disclose
 
Suxia Luo
Consulting or Advisory Role - KYM Biosciences
 
Jie Chen
No Relationships to Disclose
 
Jianwei Yang
No Relationships to Disclose
 
Zhengbo Song
No Relationships to Disclose
 
Yongsheng Li
No Relationships to Disclose
 
Ying Tang
No Relationships to Disclose
 
Peng Zhao
No Relationships to Disclose
 
Baorui Liu
No Relationships to Disclose
 
Junhe Li
No Relationships to Disclose
 
Sheng Hu
No Relationships to Disclose
 
Zhiye Zhang
No Relationships to Disclose
 
Lin Wu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Hengrui Medicine; Innovate Biopharmaceuticals; Lilly; MSD; Pfizer; Roche China
 
Lijie Song
No Relationships to Disclose
 
Xielin Feng
No Relationships to Disclose
 
Yunfeng Shan
No Relationships to Disclose
 
Tao Liu
Employment - Leads Biolabs
 
Shengli Cai
Employment - Leads Biolabs
Leadership - Leads Biolabs
 
Lin Shen
No Relationships to Disclose